NVO Novo Nordisk A/S Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
06:22
Jun 03
Jun 03
Novo Nordisk launches the Wegovy pill in the UAE, signaling global expansion ambitions but with limited near-term TAM impact.
LOW
04:24
Jun 03
Jun 03
Denmark's economy is forecast to grow 3.7% this year, beating prior estimates due to strong export gains driven by demand for Novo Nordisk products, according to Danske Bank.
21:07
Jun 01
Jun 01
Author lists their top five positions with percentage gains but provides no forward-looking view or trade idea, only past performance.
LOW
11:48
May 29
May 29
Buy NVO based on author's disclosure of a large existing position as second-largest holding in his portfolio, indicating strong long-term conviction despite acknowledging competitor superiority.
MED
12:46
May 28
May 28
NVO cited as the catalyst forcing GLP-1 price competition; co-mentioned as the aggressor in category-wide pricing pressure.
LOW
12:54
May 25
May 25
The tweet shares a chart showing Eli Lilly launched an oral pill, but provides no forward-looking opinion or trade idea on either LLY or Novo Nordisk.
LOW
05:26
May 21
May 21
Points to a must-read piece on Novo Nordisk's Canadian patent issues; fundamental catalyst noted, no personal bullish or bearish stance expressed.
LOW
07:29
May 14
May 14
Long NVO — speaker discloses bias as holder, argues NVO is still a good long-term investment after rerating; risk/reward as good as it's ever been despite guidance cuts and negative 2026 growth forecasts.
MED
00:37
May 13
May 13
Novo Nordisk reports that a higher-dose Wegovy shot helped patients lose 28% of their weight, but the tweet is a factual report without a forward-looking opinion.
HIGH
22:25
May 11
May 11
Adam May argues that Hims & Hers' poor earnings and margin compression occurred before the full impact of losing its compounded semaglutide business, warning of worse results in Q2.
HIGH
04:51
May 09
May 09
The author nostalgically contrasts extinct value/dividend investors in FISV, PYPL, and NVO with massive gains in semiconductor stocks INTC and SNDK, implying a market shift favoring AI narratives over traditional value plays.
HIGH
00:49
May 09
May 09
Bearish view on NVO due to headwinds from Novo's injectable installed base, category price compression, and structural pressures from IRA 2027 and loss of exclusivity; bullish case hinges only on injectable Wegovy improvement.
HIGH
15:50
May 08
May 08
The user praises Novo Nordisk for keeping its oral Wegovy simple, but the tweet lacks a forward-looking directional view or trade idea.
HIGH
17:44
May 07
May 07
The author lays out a concentrated long biotech portfolio on a down XBI day, highlighting ABVX as a major position and listing other names under consideration, reflecting a bullish sector outlook despite short-term losses.
HIGH
12:31
May 07
May 07
The author argues Amazon's aggressive moves into GLP-1 fulfillment, leveraging its e-commerce logistics, will make it a major healthcare player, while Novo Nordisk's stock reaction is seen as a headline-driven blip.
HIGH
18:18
May 06
May 06
Novo Nordisk obesity leadership strengthens.
Novo Nordisk's oral Wegovy pill is superior to competitors in efficacy (17% weight loss vs ~30% higher than competitor), safety backed by 15 million patient-years, tolerability, and lack of drug interaction restrictions (e.g., no need to stop birth control). This has driven 65% of new obesity prescriptions to Novo Nordisk in the latest quarter. Combined with a strong pipeline (cagrisema, zenamtite, UBT251) and an open M&A mindset to build the broadest pipeline, the company is positioned to retain leadership in the obesity market and deliver continued growth.
HIGH
11:09
May 06
May 06
Novo Nordisk strong launch continues
Novo Nordisk is well-positioned with the Wegovy pill launch exceeding expectations, a unique cardiovascular label, stable pricing, and a rich pipeline, supporting continued growth.
MED
08:34
May 06
May 06
Adam May mocks analysts who cited Wegovy pill size as a bear point, highlighting the small pill in Novo Nordisk's video announcement.
HIGH
05:54
May 06
May 06
Long NVO ahead of European open after company raised guidance, signaling stronger fundamentals and likely positive price reaction.
HIGH
19:57
May 05
May 05
User u/SnooTomatoes2318 (6 upvotes) says “NVO it’s time to go parabolic. pull LLY moves, i won’t curse you again.” Implies NVO should mimic LLY’s recent gains. Novo Nordisk has lagged Eli Lilly despite obesity market leadership. If rotation into pharma or a catalyst emerges, NVO could catch up. Play the relative value gap versus LLY; community sees overdue rally. LLY has stronger pipeline; NVO may stay range‑bound; low upvote count limits conviction.
MED
20:28
May 04
May 04
Adam May makes a lighthearted linguistic correction about Novo Nordisk's name in a reply, with no market analysis or directional view.
HIGH
00:50
May 02
May 02
Go long NVO on the thesis that its aggressive M&A spree and competitive actions (suing HIMS) signal a strategic pivot that could re-rate the stock after 2025's decline.
HIGH
00:41
May 02
May 02
Long NVO based on market overreaction to the cagrisema readout, while the OW launch fundamentals remain strong, creating a mispricing opportunity.
HIGH
00:14
May 02
May 02
The author mocks a past buying opportunity at $40 compared to current $130 price, but expresses no forward-looking view on Novo Nordisk.
HIGH
20:29
May 01
May 01
Adam May clarifies he is long Novo Nordisk since late February 2026 and views its aggressive M&A commentary as bullish for small-cap biotechs, not for NVO equity.
HIGH
20:24
May 01
May 01
Buy NVO on a contrarian thesis: the record drop from a trial failure was overdone because failure was widely expected, offering a buying opportunity.
HIGH
20:13
May 01
May 01
Adam May angrily denies being bullish on NVO stock in a heated reply, with no forward-looking market analysis or trade idea.
HIGH
20:04
May 01
May 01
Bearish view on NVO because speaker was never bullish on the stock and is currently profiting from a short position, implying ongoing bearish view.
HIGH
18:20
May 01
May 01
Buy NVO because the higher dosing regimen makes the drug clinically superior to the market's perception, creating a slow-but-steady revaluation that allows accumulation.
HIGH
12:18
May 01
May 01
Adam May replies to Mr_Derivatives with "More to come" regarding Novo Nordisk, but provides no explicit directional view or actionable trade idea.
HIGH
About NVO Analyst Coverage
Buzzberg tracks NVO (Novo Nordisk A/S) across 27 sources. 42 bullish vs 6 bearish calls from 55 analysts. Sentiment: predominantly bullish (28%). 129 total trade ideas tracked.